MedTrace Logo

QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt

NCT04159571 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-21

Study results available
· View outcomes & findings →

Summary

Cigarette smoking constitutes the greatest preventable cause of mortality and morbidity in the US. The most critical period for long term success of smoking cessation appears to be in the first 7 days after the quit date. A metaanalysis of 3 pharmacotherapy trials revealed that abstinence during the first 7 days was the strongest predictor of 6 month outcomes (n=1649; Odds ratio: 1.4, P \<0.0001; Ashare et al. 2013). Prodigious relapse rates during this first week of smoking cessation are likely due to behavioral and neurobiological factors that contribute to high cue-associated craving and low executive control over smoking. The long term goal of the research is to develop evidence-based transcranial magnetic stimulation protocols to facilitate abstinence during this critical period.

Conditions

  • Smoking
  • Smoking Cessation
  • Craving
  • Addiction
  • Addiction Nicotine
  • Nicotine Dependence
  • Cigarette Smoking

Interventions

DEVICE

Real TBS to the vmPFC

This will be delivered with the Magventure Magpro system; active sham coil (double blinded)

DEVICE

Sham cTBS to the vmPFC

The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.

Sponsors & Collaborators

  • Virginia Tech Carilion School of Medicine and Research Institute

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Merideth A. Addicott, PhD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-20
Primary Completion
2022-11-23
Completion
2022-11-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04159571 on ClinicalTrials.gov